Table 5.

Published data on hepatitis C seroprevalence among special unrepresentative populations in Malawi: Published data from 1990 to 2018

Population	Ref	Year	Location	Method	Prevalence (n/total)	Prevalence (%, (95% CI))
Prisoners	[28]	2007	Chichiri Prison, Blantyre	Anti-HCV (Biotec)	0/164	0.0 (0.0, 2.3)
Adult inpatients (Dermatology, Urology)	[32]	1996	KCH, Lilongwe	Anti-HCV EIA (Roche) Confirmed with Anti-HCV (Abbott)	13/333	3.9 (2.3, 6.6)
Adult medical inpatients	[27]	2004	Medical ward, QECH, Blantyre	HCV Ag/Ab (Monolisa, Biorad) confirmed with Immunoassay (Innogenetics)	9/202	4.5 (2.4, 8.2)
Malawian women and children with childhood malignancies	[34]	2006–10	QECH, Blantyre	HBV ELISA (MP Biomedicals)	Mothers: 2/418	0.5 (0.1, 1.7)
				Confirmed by HCV BLOT (MP Biomedicals)	Children: 1/418	0.2 (0.0, 1.3)

Abbreviations: Biotec: Dorset, United Kingdom; Roche: Basel, Switzerland; Abbott: Illinois, USA; Innogenetics: Ghent, Belgium; MP Biomedicals: California, USAKCH Kamuzu Central Hospital, QECH Queen Elizabeth Central Hospital, HCV hepatitis C virus